clinical trial · NCT03407144
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 340
Hodgkin Lymphomapembrolizumabdoxorubicinvinblastinedacarbazinecyclophosphamidevincristineprednisone/prednisolonebleomycin
brief summary
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
started
Apr 9, 2018
primary completion
Nov 6, 2026
completion
Nov 6, 2026
last updated
Feb 19, 2026
detailed description
Group 1 will consist of low-risk participants with cHL Stages IA, IB and IIA without bulky disease. Group 2 will consist of high-risk participants with cHL Stages IIEB, IIIEA, IIIEB, IIIB, IVA and IVB.
official title
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol